Camurus AB (publ) (CAMX.ST)
SEK 574.5
(1.77%)
SEK 574.5
(1.77%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.9 Billion SEK | 46.14% |
| 2022 | 1.3 Billion SEK | 20.67% |
| 2021 | 1.08 Billion SEK | 3.62% |
| 2020 | 1.04 Billion SEK | 35.24% |
| 2019 | 772.04 Million SEK | 111.68% |
| 2018 | 364.72 Million SEK | -23.37% |
| 2017 | 475.93 Million SEK | -25.61% |
| 2016 | 639.77 Million SEK | -21.63% |
| 2015 | 816.34 Million SEK | 293.1% |
| 2014 | 207.66 Million SEK | 85.99% |
| 2013 | 111.65 Million SEK | 94.51% |
| 2012 | 57.4 Million SEK | -34.65% |
| 2011 | 87.84 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.06 Billion SEK | 60.43% |
| 2024 Q2 | 3.43 Billion SEK | 12.13% |
| 2023 Q3 | 1.84 Billion SEK | 3.84% |
| 2023 FY | 1.9 Billion SEK | 46.14% |
| 2023 Q1 | 1.34 Billion SEK | 3.41% |
| 2023 Q4 | 1.9 Billion SEK | 3.59% |
| 2023 Q2 | 1.77 Billion SEK | 31.38% |
| 2022 Q1 | 1.09 Billion SEK | 0.96% |
| 2022 FY | 1.3 Billion SEK | 20.67% |
| 2022 Q4 | 1.3 Billion SEK | 5.83% |
| 2022 Q3 | 1.23 Billion SEK | 8.9% |
| 2022 Q2 | 1.13 Billion SEK | 3.7% |
| 2021 Q4 | 1.08 Billion SEK | 3.43% |
| 2021 Q1 | 1.02 Billion SEK | -1.39% |
| 2021 Q2 | 1.04 Billion SEK | 1.57% |
| 2021 Q3 | 1.04 Billion SEK | 0.03% |
| 2021 FY | 1.08 Billion SEK | 3.62% |
| 2020 FY | 1.04 Billion SEK | 35.24% |
| 2020 Q2 | 723.37 Million SEK | -0.95% |
| 2020 Q3 | 989.62 Million SEK | 36.81% |
| 2020 Q4 | 1.04 Billion SEK | 5.5% |
| 2020 Q1 | 730.35 Million SEK | -5.4% |
| 2019 FY | 772.04 Million SEK | 111.68% |
| 2019 Q4 | 772.04 Million SEK | 36.54% |
| 2019 Q3 | 565.43 Million SEK | -9.55% |
| 2019 Q2 | 625.16 Million SEK | -11.12% |
| 2019 Q1 | 703.4 Million SEK | 92.86% |
| 2018 Q3 | 441.45 Million SEK | -9.93% |
| 2018 Q2 | 490.13 Million SEK | 12.45% |
| 2018 Q1 | 435.87 Million SEK | -8.42% |
| 2018 FY | 364.72 Million SEK | -23.37% |
| 2018 Q4 | 364.72 Million SEK | -17.38% |
| 2017 Q3 | 520.41 Million SEK | -8.76% |
| 2017 FY | 475.93 Million SEK | -25.61% |
| 2017 Q1 | 597.59 Million SEK | -6.59% |
| 2017 Q4 | 475.93 Million SEK | -8.55% |
| 2017 Q2 | 570.4 Million SEK | -4.55% |
| 2016 FY | 639.77 Million SEK | -21.63% |
| 2016 Q4 | 639.77 Million SEK | -1.42% |
| 2016 Q3 | 648.97 Million SEK | -1.71% |
| 2016 Q2 | 660.26 Million SEK | -2.36% |
| 2016 Q1 | 676.18 Million SEK | -17.17% |
| 2015 Q1 | - SEK | -100.0% |
| 2015 Q4 | 816.34 Million SEK | 288.33% |
| 2015 FY | 816.34 Million SEK | 293.1% |
| 2015 Q3 | 210.22 Million SEK | 0.0% |
| 2014 Q4 | 207.66 Million SEK | 0.0% |
| 2014 FY | 207.66 Million SEK | 85.99% |
| 2013 FY | 111.65 Million SEK | 94.51% |
| 2012 FY | 57.4 Million SEK | -34.65% |
| 2011 FY | 87.84 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -1510.654% |
| Ziccum AB (publ) | 14.97 Million SEK | -12642.586% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -9419.585% |
| BioArctic AB (publ) | 1.18 Billion SEK | -60.851% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -2958.531% |
| Mendus AB (publ) | 755.95 Million SEK | -152.373% |
| Genovis AB (publ.) | 288.85 Million SEK | -560.472% |
| Intervacc AB (publ) | 259.61 Million SEK | -634.876% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -4446.867% |
| Active Biotech AB (publ) | 44 Million SEK | -4235.955% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -584.432% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -2969.604% |
| Aptahem AB (publ) | 63.02 Million SEK | -2927.087% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -284.449% |
| Kancera AB (publ) | 65.64 Million SEK | -2806.357% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -443.022% |
| Fluicell AB (publ) | 9.34 Million SEK | -20326.338% |
| Saniona AB (publ) | 64.14 Million SEK | -2874.323% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -5577.698% |
| Biovica International AB (publ) | 131.4 Million SEK | -1351.829% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -3500.679% |
| AcouSort AB (publ) | 34.51 Million SEK | -5427.83% |
| Xintela AB (publ) | 18.39 Million SEK | -10271.405% |
| Abliva AB (publ) | 87.49 Million SEK | -2080.391% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | -150.963% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | -51.608% |
| OncoZenge AB (publ) | 20.34 Million SEK | -9279.646% |
| Amniotics AB (publ) | 26.08 Million SEK | -7213.578% |
| 2cureX AB (publ) | 16.62 Million SEK | -11375.609% |
| CombiGene AB (publ) | 120.61 Million SEK | -1481.783% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -31294.109% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | -0.383% |
| Corline Biomedical AB | 100.1 Million SEK | -1805.819% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -977.128% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -1256.942% |
| I-Tech AB | 152.44 Million SEK | -1151.497% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | -87.401% |
| Cyxone AB (publ) | 43.65 Million SEK | -4270.221% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -2324.414% |
| Biosergen AB | 7.2 Million SEK | -26393.82% |
| Cantargia AB (publ) | 223.71 Million SEK | -752.802% |
| NextCell Pharma AB | 81.28 Million SEK | -2246.988% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | -149.303% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -6222.931% |
| Nanologica AB (publ) | 77.42 Million SEK | -2363.961% |
| SynAct Pharma AB | 228.01 Million SEK | -736.693% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -7028.573% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -8690.632% |
| LIDDS AB (publ) | 17.65 Million SEK | -10706.117% |
| Lipum AB (publ) | 12.11 Million SEK | -15654.088% |
| BioInvent International AB (publ) | 1.4 Billion SEK | -36.255% |
| Alzinova AB (publ) | 123.18 Million SEK | -1448.693% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -700.334% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -22464.4% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -2138.516% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -12730.856% |
| Simris Alg AB (publ) | 174.55 Million SEK | -992.981% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -779.026% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -191.935% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -2091.083% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -6592.227% |